cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.10318022
title: Antepartum fibrinogen concentration as a predictor of bleeding complications

description: The objective of this study was to examine the predictive value of fibrinogen concentration for bleeding complications among women presenting for delivery and for whom a fibrinogen level was measured before delivery. This was a nested case-control study using a cohort of all women who delivered at our institution from October 2001 to July 2016 and in whom a fibrinogen concentration was obtained within 48 hours before delivery. We identified all cases that had one or more of the following events: (1) postpartum hemorrhage; (2) postpartum hysterectomy; (3) transfusion of select blood products; or (4) a ≥ 33% decrease in hematocrit from the first hematocrit measured during the hospital stay to any subsequent hematocrit value drawn either simultaneously with or following the fibrinogen concentration measurement. We included the first case or control delivery for a given woman. Controls were the next one or two consecutive deliveries without a bleeding complication and matched for number of fetuses. We used logistic regression to calculate the odds ratio and 95% confidence intervals and calculated the area under the receiver operating characteristic curve. We identified 424 cases and 801 controls. The mean predelivery fibrinogen concentration was significantly lower in cases (425 ± 170 mg/dL) than controls (523 ± 122 ng/mL) for all case types combined (<i>p</i> p Antepartum fibrinogen concentration was significantly lower among women who developed bleeding complications, though these differences may not be large enough to provide clinically meaningful critical values. Nevertheless, a higher threshold for the critical value during pregnancy should be considered.
DOI: 10.6084/m9.figshare.10318028
title: Major dietary patterns in relation to preeclampsia among Iranian pregnant women: a case–control study

description: Preeclampsia is a pregnancy disorder that increases the risk of prenatal and maternal complications. Therefore, prevention of preeclampsia requires identifying its preventable risk factors such as dietary patterns. This study aimed to investigate the relationship between the major dietary patterns and preeclampsia. In this case<b>–</b>control study, the dietary patterns of a total of 510 pregnant women were investigated. Data on their dietary intake, sociodemographics, and daily physical activity levels were collected using a 198 item semi-quantitative food frequency questionnaire, a sociodemographic questionnaire, and a physical activity questionnaire, respectively. To identify the major dietary patterns and to model the relationship between dietary patterns and preeclampsia, factor analysis and unconditional logistic regression were employed, respectively. The three major dietary patterns identified were as follows: healthy dietary pattern (i.e. high in fruits, low-fat dairy, dried fruits, nuts, vegetables, fruit juice, liquid oil, and tomatoes), western dietary pattern (i.e. high in red meat, processed meat, fried potatoes, and pickles), and Iranian traditional dietary pattern (i.e. high in eggs, potatoes, and legumes). After adjustment for confounding factors, we found that with an increase in the healthy dietary pattern score, the odds of preeclampsia were reduced to 87.5% (OR = 0.125, 95%CI: 0.070–0.221, <i>p</i> p p The findings showed that the western dietary pattern had a direct relationship and the healthy and Iranian traditional patterns had a reverse relationship with preeclampsia.
DOI: 10.6084/m9.figshare.10318028.v1
title: Major dietary patterns in relation to preeclampsia among Iranian pregnant women: a case–control study

description: Preeclampsia is a pregnancy disorder that increases the risk of prenatal and maternal complications. Therefore, prevention of preeclampsia requires identifying its preventable risk factors such as dietary patterns. This study aimed to investigate the relationship between the major dietary patterns and preeclampsia. In this case<b>–</b>control study, the dietary patterns of a total of 510 pregnant women were investigated. Data on their dietary intake, sociodemographics, and daily physical activity levels were collected using a 198 item semi-quantitative food frequency questionnaire, a sociodemographic questionnaire, and a physical activity questionnaire, respectively. To identify the major dietary patterns and to model the relationship between dietary patterns and preeclampsia, factor analysis and unconditional logistic regression were employed, respectively. The three major dietary patterns identified were as follows: healthy dietary pattern (i.e. high in fruits, low-fat dairy, dried fruits, nuts, vegetables, fruit juice, liquid oil, and tomatoes), western dietary pattern (i.e. high in red meat, processed meat, fried potatoes, and pickles), and Iranian traditional dietary pattern (i.e. high in eggs, potatoes, and legumes). After adjustment for confounding factors, we found that with an increase in the healthy dietary pattern score, the odds of preeclampsia were reduced to 87.5% (OR = 0.125, 95%CI: 0.070–0.221, <i>p</i> p p The findings showed that the western dietary pattern had a direct relationship and the healthy and Iranian traditional patterns had a reverse relationship with preeclampsia.
DOI: 10.6084/m9.figshare.10482677
title: Perinatal death by bile acid levels in intrahepatic cholestasis of pregnancy: a systematic review

description: Intrahepatic cholestasis of pregnancy (ICP) is characterized by the elevation of total bile acids (TBAs). The primary concern in women with ICP is the increased risk of stillbirth. ICP is generally considered as “mild” when TBA levels range from 10 to 39 µmol/L and “severe” with levels greater than 40 µmol/L, although levels of TBA ≥100 µmol/L have been also considered as a further threshold of severity. To quantify the association between different severities of ICP (TBA 10–39, 40–99, and ≥100 µmol/L) and perinatal death. Medline, Embase, Scopus, Web of Sciences, and ClinicalTrial.gov were searched from the inception of each database to February 2019. Randomized, cohort, case-control, or case series studies reporting maternal and perinatal outcomes on women with ICP by the three prespecified TBA levels (10–39, 40–99, and ≥100 µmol/L) were included. We excluded multiple gestations and trials which included an intervention. The analysis was performed with Pearson chi-square and Fisher’s exact test as appropriate. Continuous outcomes were compared using metaregression with inverse variance weighting using reported sample sizes and standard deviations. Pairwise comparisons used a Bonferroni correction to control for multiple testing. Six articles including 1280 singleton pregnancies affected by ICP were included in the systematic review. Out of the 1280 singleton pregnancies affected by ICP included, 118 had ICP with TBA ≥100 µmol/L. Perinatal death was more common in women with TBA ≥100 µmol/L (0.4% for TBA 10-39 μmol/L <i>versus</i> 0.3% for TBA 40-99 μmol/L <i>versus</i> 6.8% for TBA ≥ 100 μmol/L, <i>p</i> versus 8.6% <i>versus</i> 18.2% respectively, <i>p</i> versus 21.6% <i>versus</i> 35.8% respectively, <i>p</i>versus 18.4% <i>versus</i> 31.6% respectively, <i>p</i> Maternal TBA ≥100 µmol/L is associated with a 6.8% incidence of perinatal death, most of which (5.9% overall) are stillbirths, while TBA &lt;100 µmol/L are associated with an incidence of perinatal death of 0.3%. It may be reasonable to consider late preterm delivery (at about 35–36 weeks) in women with TBA ≥100 µmol/L.
DOI: 10.6084/m9.figshare.10318022.v1
title: Antepartum fibrinogen concentration as a predictor of bleeding complications

description: The objective of this study was to examine the predictive value of fibrinogen concentration for bleeding complications among women presenting for delivery and for whom a fibrinogen level was measured before delivery. This was a nested case-control study using a cohort of all women who delivered at our institution from October 2001 to July 2016 and in whom a fibrinogen concentration was obtained within 48 hours before delivery. We identified all cases that had one or more of the following events: (1) postpartum hemorrhage; (2) postpartum hysterectomy; (3) transfusion of select blood products; or (4) a ≥ 33% decrease in hematocrit from the first hematocrit measured during the hospital stay to any subsequent hematocrit value drawn either simultaneously with or following the fibrinogen concentration measurement. We included the first case or control delivery for a given woman. Controls were the next one or two consecutive deliveries without a bleeding complication and matched for number of fetuses. We used logistic regression to calculate the odds ratio and 95% confidence intervals and calculated the area under the receiver operating characteristic curve. We identified 424 cases and 801 controls. The mean predelivery fibrinogen concentration was significantly lower in cases (425 ± 170 mg/dL) than controls (523 ± 122 ng/mL) for all case types combined (<i>p</i> p Antepartum fibrinogen concentration was significantly lower among women who developed bleeding complications, though these differences may not be large enough to provide clinically meaningful critical values. Nevertheless, a higher threshold for the critical value during pregnancy should be considered.
DOI: 10.6084/m9.figshare.10482677.v1
title: Perinatal death by bile acid levels in intrahepatic cholestasis of pregnancy: a systematic review

description: Intrahepatic cholestasis of pregnancy (ICP) is characterized by the elevation of total bile acids (TBAs). The primary concern in women with ICP is the increased risk of stillbirth. ICP is generally considered as “mild” when TBA levels range from 10 to 39 µmol/L and “severe” with levels greater than 40 µmol/L, although levels of TBA ≥100 µmol/L have been also considered as a further threshold of severity. To quantify the association between different severities of ICP (TBA 10–39, 40–99, and ≥100 µmol/L) and perinatal death. Medline, Embase, Scopus, Web of Sciences, and ClinicalTrial.gov were searched from the inception of each database to February 2019. Randomized, cohort, case-control, or case series studies reporting maternal and perinatal outcomes on women with ICP by the three prespecified TBA levels (10–39, 40–99, and ≥100 µmol/L) were included. We excluded multiple gestations and trials which included an intervention. The analysis was performed with Pearson chi-square and Fisher’s exact test as appropriate. Continuous outcomes were compared using metaregression with inverse variance weighting using reported sample sizes and standard deviations. Pairwise comparisons used a Bonferroni correction to control for multiple testing. Six articles including 1280 singleton pregnancies affected by ICP were included in the systematic review. Out of the 1280 singleton pregnancies affected by ICP included, 118 had ICP with TBA ≥100 µmol/L. Perinatal death was more common in women with TBA ≥100 µmol/L (0.4% for TBA 10-39 μmol/L <i>versus</i> 0.3% for TBA 40-99 μmol/L <i>versus</i> 6.8% for TBA ≥ 100 μmol/L, <i>p</i> versus 8.6% <i>versus</i> 18.2% respectively, <i>p</i> versus 21.6% <i>versus</i> 35.8% respectively, <i>p</i>versus 18.4% <i>versus</i> 31.6% respectively, <i>p</i> Maternal TBA ≥100 µmol/L is associated with a 6.8% incidence of perinatal death, most of which (5.9% overall) are stillbirths, while TBA &lt;100 µmol/L are associated with an incidence of perinatal death of 0.3%. It may be reasonable to consider late preterm delivery (at about 35–36 weeks) in women with TBA ≥100 µmol/L.
DOI: 10.6084/m9.figshare.14637267
title: Supplementary Material for: Risk Factors for Gallstones and Cholecystectomy: a Large-Scale Population-Based Prospective Cohort Study in Japan

description: Medicine
DOI: 10.6084/m9.figshare.16635103
title: Supplementary Material for: Effect of Probiotic Supplementation on Glycemic Outcomes in Patients with Abnormal Glucose Metabolism: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

description: <b><i>Introduction:</i></b> The effectiveness of probiotics in patients with abnormal glucose metabolism has not been clearly demonstrated. It is also unclear if outcomes are consistent across different probiotic formulations. <b><i>Methods:</i></b> A literature search was conducted using PubMed, EMBASE, and Cochrane CENTRAL database from inception through May 2020. Randomized controlled trials that evaluated the effect of probiotics on fasting blood glucose (FBG) or hemoglobin A1c (HbA1c) in patients with prediabetes, type 2 diabetes mellitus, or gestational diabetes were included. Outcomes of interest included FBG, HbA1c, fasting insulin, homeostatic model assessment of insulin resistance (HOMA-IR), homeostatic model assessment of β-cell function (HOMA-B), and quantitative insulin sensitivity check index (QUICKI). Weighted mean difference (WMD) and 95% confidence intervals (CIs) were calculated using the DerSimonian and Laird random-effects model. <b><i>Results:</i></b> 31 studies involving 1,948 participants were included in this analysis. Compared to control, probiotics had a significant favorable effect on FBG (WMD −5.77 mg/dL, 95% CI −8.48 to −3.06), HbA1c (WMD −0.32%, 95% CI −0.47 to −0.18), fasting insulin (WMD −2.95 µIU/mL, 95% CI −3.76 to −2.14), HOMA-IR (WMD −0.82, 95% CI −1.05 to −0.59), HOMA-B (WMD −14.86, 95% CI −24.57 to −5.16), and QUICKI (WMD 0.015, 95% CI 0.011–0.019). Further, probiotics were associated with favorable outcomes on all parameters at doses between 1 and 10 × 10<sup>9</sup> colony-forming unit per day (<i>p</i> &lt; 0.004 for all) and formulations containing 2–4 strains (<i>p</i> &lt; 0.05 for all). <b><i>Discussion/Conclusion:</i></b> Probiotics appear to have a modest effect on glycemic parameters in patients with abnormal glucose metabolism. Due to the limited number of trials conducted in patients with prediabetes, more studies are warranted in this population.
DOI: 10.6084/m9.figshare.16635103.v1
title: Supplementary Material for: Effect of Probiotic Supplementation on Glycemic Outcomes in Patients with Abnormal Glucose Metabolism: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

description: <b><i>Introduction:</i></b> The effectiveness of probiotics in patients with abnormal glucose metabolism has not been clearly demonstrated. It is also unclear if outcomes are consistent across different probiotic formulations. <b><i>Methods:</i></b> A literature search was conducted using PubMed, EMBASE, and Cochrane CENTRAL database from inception through May 2020. Randomized controlled trials that evaluated the effect of probiotics on fasting blood glucose (FBG) or hemoglobin A1c (HbA1c) in patients with prediabetes, type 2 diabetes mellitus, or gestational diabetes were included. Outcomes of interest included FBG, HbA1c, fasting insulin, homeostatic model assessment of insulin resistance (HOMA-IR), homeostatic model assessment of β-cell function (HOMA-B), and quantitative insulin sensitivity check index (QUICKI). Weighted mean difference (WMD) and 95% confidence intervals (CIs) were calculated using the DerSimonian and Laird random-effects model. <b><i>Results:</i></b> 31 studies involving 1,948 participants were included in this analysis. Compared to control, probiotics had a significant favorable effect on FBG (WMD −5.77 mg/dL, 95% CI −8.48 to −3.06), HbA1c (WMD −0.32%, 95% CI −0.47 to −0.18), fasting insulin (WMD −2.95 µIU/mL, 95% CI −3.76 to −2.14), HOMA-IR (WMD −0.82, 95% CI −1.05 to −0.59), HOMA-B (WMD −14.86, 95% CI −24.57 to −5.16), and QUICKI (WMD 0.015, 95% CI 0.011–0.019). Further, probiotics were associated with favorable outcomes on all parameters at doses between 1 and 10 × 10<sup>9</sup> colony-forming unit per day (<i>p</i> &lt; 0.004 for all) and formulations containing 2–4 strains (<i>p</i> &lt; 0.05 for all). <b><i>Discussion/Conclusion:</i></b> Probiotics appear to have a modest effect on glycemic parameters in patients with abnormal glucose metabolism. Due to the limited number of trials conducted in patients with prediabetes, more studies are warranted in this population.
DOI: 10.6084/m9.figshare.16635055
title: Supplementary Material for: Dyslipidemia in Chronic Kidney Disease: Contemporary Concepts and Future Therapeutic Perspectives

description: <b><i>Background:</i></b> Chronic kidney disease (CKD) is an increasingly prevalent disease state met with great morbidity and mortality primarily resulting from the high incidence of adverse cardiovascular outcomes. Therapeutic strategies in this patient population aim at controlling modifiable cardiovascular risk factors, including dyslipidemia. <b><i>Summary:</i></b> In this review article, we first provide the latest pathophysiologic evidence regarding the altered dyslipidemia pattern in CKD, followed by its contemporary management according to the latest guidelines. Moreover, we present the current progress regarding the emerging therapeutic strategies. <b><i>Key Messages:</i></b> The presence of renal impairment leads to alterations in cholesterol structure, metabolism, and reverse transport paired with increased oxidative stress. Statins remain the cornerstone of dyslipidemia management in patients with kidney dysfunction who are at risk for cardiovascular events. However, their efficacy is debatable in end-stage renal disease under renal replacement therapy. Therefore, novel treatment approaches aiming at hypertriglyceridemia, proprotein convertase subtilisin/kexin type 9, and lipoprotein(a) are under rigorous investigation while the research of gut microbiome might provide additional mechanistic and therapeutic insight.
DOI: 10.6084/m9.figshare.16635055.v1
title: Supplementary Material for: Dyslipidemia in Chronic Kidney Disease: Contemporary Concepts and Future Therapeutic Perspectives

description: <b><i>Background:</i></b> Chronic kidney disease (CKD) is an increasingly prevalent disease state met with great morbidity and mortality primarily resulting from the high incidence of adverse cardiovascular outcomes. Therapeutic strategies in this patient population aim at controlling modifiable cardiovascular risk factors, including dyslipidemia. <b><i>Summary:</i></b> In this review article, we first provide the latest pathophysiologic evidence regarding the altered dyslipidemia pattern in CKD, followed by its contemporary management according to the latest guidelines. Moreover, we present the current progress regarding the emerging therapeutic strategies. <b><i>Key Messages:</i></b> The presence of renal impairment leads to alterations in cholesterol structure, metabolism, and reverse transport paired with increased oxidative stress. Statins remain the cornerstone of dyslipidemia management in patients with kidney dysfunction who are at risk for cardiovascular events. However, their efficacy is debatable in end-stage renal disease under renal replacement therapy. Therefore, novel treatment approaches aiming at hypertriglyceridemia, proprotein convertase subtilisin/kexin type 9, and lipoprotein(a) are under rigorous investigation while the research of gut microbiome might provide additional mechanistic and therapeutic insight.
DOI: 10.6084/m9.figshare.16635118
title: teknostres

description: data set of technostress study
DOI: 10.5281/zenodo.5513347
title: Drought assessment of China in 2002–2017 based on a Detrended Combined Climatological Deviation Index

description: Detrended-CCDI.zip:The monthly drought results were identified by Detrended-CCDI from April 2002 to August 2017.Detrended-CCDI was calculated using GRACE data and precipitation data after the seasonal decomposition of time series based on the Loess (STL) method. Drought frenquency.zip:Drought frequency is the “n/m” ratio per pixel. “n” is the number of consecutive months (more than or equal to 3 months) in which Detrended-CCDI was less than or equal to -0.53, and “m” is the total number of months in the study period. Drought trend.zip:Drought trend was obtained using the modified Mann-Kendall (MMK) trend test method. Regional drought events.zip:A regional drought event is defined when the area where Detrended-CCDI is less than or equal to - 0.53 exceeds 100,000 km<sup>2</sup> and the duration is more than 3 months. The severity of drought events is expressed by the average cumulative value of monthly Detrended-CCDI pixels.
DOI: 10.6084/m9.figshare.16635152
title: Prediction of power conversion efficiency of phenothiazine-based dye-sensitized solar cells using Monte Carlo method with index of ideality of correlation

description: Simplified molecular-input line-entry system (SMILES) notation and inbuilt Monte Carlo algorithm of CORAL software were employed to construct generative and prediction QSPR models for the analysis of the power conversion efficiency (PCE) of 215 phenothiazine derivatives. The dataset was divided into four splits and each split was further divided into four sets. A hybrid descriptor, a combination of SMILES and hydrogen suppressed graph (HSG), was employed to build reliable and robust QSPR models. The role of the index of ideality of correlation (IIC) was also studied in depth. We performed a comparative study to predict PCE using two target functions (TF<sub>1</sub> without IIC and TF<sub>2</sub> with IIC). Eight QSPR models were developed and the models developed with TF<sub>2</sub> was shown robust and reliable. The QSPR model generated from split 4 was considered a leading model. The different statistical benchmarks were computed for the lead model and these were rtraining set2=0.7784; rinvisible training set2=0.7955; rcalibration set2=0.7738; rvalidation set2=0.7506; Qtraining set2=0.7691; Qinvisible training set2=0.7850; Qcalibration set2=0.7501; Qvalidation set2=0.7085; IIC<sub>training set</sub> = 0.8590; IIC<sub>invisible training set</sub> = 0.8297; IIC<sub>calibration set</sub> = 0.8796; IIC<sub>validation set</sub> = 0.8293, etc. The promoters of increase and decrease of endpoint PCE were also extracted.
DOI: 10.6084/m9.figshare.16635158
title: Combined 4D-QSAR and target-based approaches for the determination of bioactive Isatin derivatives

description: The hybrid method of the Electron-Conformational Genetic Algorithm (EC-GA) was used to determine the pharmacophore groups and to estimate anticancer activity in isatin derivatives using a robust 4D-QSAR software (EMRE). To build the model, each compound is represented by a set of conformers rather than a single conformation. The Electron Conformational Matrix of Congruity (ECMC) is composed via EMRE software. Electron Conformational Submatrix of Activity (ECSA) was calculated by the comparison of these matrices. Genetic algorithm was used to select important variables to predict theoretical activity. The model with the best seven parameters produced satisfactory results. The E statistics technique was applied to the generated EC–GA model to evaluate the individual contribution of each of the descriptors on biological activity. The <i>r</i><sup>2</sup> and <i>q</i><sup>2</sup> values of the training set compounds were found to be 0.95 and 0.93, respectively. Because no previous 4D-QSAR studies on isatin derivatives have been conducted, this study is important in the development of new isatin derivatives. In this study, 27 isatin derivatives whose activities were estimated using the hybrid EC-GA method were also investigated through molecular docking and molecular dynamics simulations for their BCL-2 inhibitory activity.